Literature DB >> 19221415

Methodological issues in primary prevention trials for neurodegenerative dementia.

Sandrine Andrieu1, Nicola Coley, Paul Aisen, Maria C Carrillo, Steven DeKosky, Jane Durga, Howard Fillit, Giovanni B Frisoni, Lutz Froelich, Serge Gauthier, Roy Jones, Linus Jönsson, Zaven Khachaturian, John C Morris, Jean-Marc Orgogozo, Pierre-Jean Ousset, Philippe Robert, Eric Salmon, Cristina Sampaio, Frans Verhey, Gordon Wilcock, Bruno Vellas.   

Abstract

The prevention of neurodegenerative dementias, such as Alzheimer's disease, is a public health priority. Due to the large numbers of affected patients, even interventions bringing about a relatively small delay in disease onset could have large public health effects. Randomized controlled trials (RCTs) are required to demonstrate the effectiveness of preventive interventions, but such trials raise specific methodological questions because they are new in the field of neurodegenerative diseases, and require large numbers of elderly subjects and lengthy follow-up periods. We performed a literature search to identify primary prevention RCTs for neurodegenerative dementia. The methodology of the trials was summarized and discussed during two expert meetings. Overall, 39 trials were identified that assessed dementia incidence or cognitive decline as a primary or secondary study outcome. Age was the most common selection criteria for target populations. Follow-up periods ranged from one month to nine years and were longest in studies measuring dementia incidence as an outcome. Results of RCTs have so far been generally negative and conflicting with those of observational studies, perhaps due to methodological issues. Future trials must therefore carefully consider the target population, outcomes and duration of follow-up to be used, and should assess the problem of attrition.

Entities:  

Mesh:

Year:  2009        PMID: 19221415     DOI: 10.3233/JAD-2009-0971

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

Review 1.  Integrating ADNI results into Alzheimer's disease drug development programs.

Authors:  Jeffrey L Cummings
Journal:  Neurobiol Aging       Date:  2010-05-05       Impact factor: 4.673

Review 2.  Diet and neurocognition: review of evidence and methodological considerations.

Authors:  Patrick J Smith; James A Blumenthal
Journal:  Curr Aging Sci       Date:  2010-02

Review 3.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

4.  Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.

Authors:  Nicola Coley; Adeline Gallini; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

5.  The nursing home population: an opportunity to make advances on research on multimorbidity and polypharmacy.

Authors:  P de Souto Barreto; B Vellas; J E Morley; Y Rolland
Journal:  J Nutr Health Aging       Date:  2013-04       Impact factor: 4.075

6.  Report of the task force on designing clinical trials in early (predementia) AD.

Authors:  P S Aisen; S Andrieu; C Sampaio; M Carrillo; Z S Khachaturian; B Dubois; H H Feldman; R C Petersen; E Siemers; R S Doody; S B Hendrix; M Grundman; L S Schneider; R J Schindler; E Salmon; W Z Potter; R G Thomas; D Salmon; M Donohue; M M Bednar; J Touchon; B Vellas
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

7.  The status of vitamins B6, B12, folate, and of homocysteine in geriatric home residents receiving laxatives or dietary fiber.

Authors:  B Sturtzel; A Dietrich; K-H Wagner; C Gisinger; I Elmadfa
Journal:  J Nutr Health Aging       Date:  2010-03       Impact factor: 4.075

8.  Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment.

Authors:  Curtis Tatsuoka; Huiyun Tseng; Judith Jaeger; Ferenc Varadi; Mark A Smith; Tomoko Yamada; Kathleen A Smyth; Alan J Lerner
Journal:  Alzheimers Res Ther       Date:  2013-03-06       Impact factor: 6.982

9.  Consequences from use of reminiscence--a randomised intervention study in ten Danish nursing homes.

Authors:  Claire Gudex; Charlotte Horsted; Anders Møller Jensen; Marianne Kjer; Jan Sørensen
Journal:  BMC Geriatr       Date:  2010-06-06       Impact factor: 3.921

10.  MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.

Authors:  B Vellas; I Carrie; S Gillette-Guyonnet; J Touchon; T Dantoine; J F Dartigues; M N Cuffi; S Bordes; Y Gasnier; P Robert; L Bories; O Rouaud; F Desclaux; K Sudres; M Bonnefoy; A Pesce; C Dufouil; S Lehericy; M Chupin; J F Mangin; P Payoux; D Adel; P Legrand; D Catheline; C Kanony; M Zaim; L Molinier; N Costa; J Delrieu; T Voisin; C Faisant; F Lala; F Nourhashémi; Y Rolland; G Abellan Van Kan; C Dupuy; C Cantet; P Cestac; S Belleville; S Willis; M Cesari; M W Weiner; M E Soto; P J Ousset; S Andrieu
Journal:  J Prev Alzheimers Dis       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.